Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens shares surged Tuesday, posting their highest price since October after The Wall Street Journal reported the drugstore chain is in talks to sell itself to a private equity firm following financial struggles and a plummeting stock price.

Walgreens Shares Surge 20% Around Reported Potential Selloff Of Drugstore Chain

Shares of Walgreens Boots Alliance (WBA 18.64%) soared 20% on Tuesday, as of 2:35 p.m. ET.

Why Walgreens Boots Alliance Soared Today

Walgreens Boots Alliance (WBA) shares soared Tuesday afternoon on a report that the struggling pharmacy chain is in talks to sell itself to Sycamore Partners.

Walgreens Stock Jumps on Talk of Potential Sale

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A) shares soared over 20% on Tuesday following reports that private equity firm Sycamore Partners is in talks to take the struggling drugstore chain private. The Wall Street Journal reported that Sycamore, known for acquiring troubled retailers like Staples and Belk, is reportedly exploring a deal that could involve breaking up Walgreens.

Walgreens shares surge amid rumored Sycamore go-private deal

Sycamore would likely sell off pieces of the business or work with partners, according to the report.

Walgreens shares soar 21% on reported talks to sell itself to Sycamore Partners

The Wall Street Journal says Walgreens and Sycamore Partners have been discussing a deal that could be finalized early next year.

Walgreens in Talks to Sell Itself, Says Report. The Stock Is Soaring.

Walgreens Boots Alliance is considering a sale to private equity firm Sycamore Partners, according to a new report.

Report: Walgreens In Talks To Go Private

Shares of Walgreens Boots Alliance Inc. were up sharply on Tuesday after the Wall Street Journal reported that the drugstore chain was in discussions to sell itself to private-equity firm Sycamore Partners.

Walgreens' stock rockets higher on report of talks to sell itself to private equity

Walgreens Boots Alliance is in talks to sell itself to private equity firm Sycamore Partners, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Walgreens in talks to sell itself to PE firm Sycamore, WSJ reports

Walgreens shares pop on report pharmacy chain could sell itself to PE firm Sycamore

Deal would cap tumultuous run for retailer whose market value shrank from a peak of over $100 billion to below $8 billion.

Walgreens Is in Talks to Sell Itself to Private-Equity Firm Sycamore Partners

DEERFIELD, Ill. and BENTONVILLE, Ark., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Soda Health today announced the expansion of the Soda Health Smart Benefits program to include Walgreens, the leading integrated independent retail pharmacy and healthcare provider, in the company's network of integrated retailers. The program, which allows recipients to receive personalized health and wellness benefits, is available to participating Medicare Advantage, Medicaid and employer benefits programs, as well as other public organizations.

Soda Health Adds Walgreens to Network of Integrated Retailers, Serving More than 100 Million Medicare Advantage and Medicaid Members

UiPath

Unity Software

As 2024 nears the end, tax loss selling is performed for tax-loss harvesting by institutional and individual investors. This is the process of selling losing positions to take the capital loss to offset capital gains in other stocks in the portfolio.

Trash to Treasure: 3 Tax-Loss Stocks Set for a January Rebound

Walgreens Boots Alliance (WBA) concluded the recent trading session at $8.56, signifying a +1.06% move from its prior day's close.

Walgreens Boots Alliance (WBA) Outperforms Broader Market: What You Need to Know

Altria

Pfizer

I'll never get tired of praising dividend stocks as the market's unsung heroes. While they aren't as sexy as high-flying growth stocks, they can be just as effective at making investors money.

Should You Buy the S&P 500's Highest-Yielding Dividend Stocks Heading Into 2025?

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Thursday, January 9, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. About Walgreens Boots Alliance Walgreens.

Walgreens Boots Alliance Schedules Fiscal 2025 First Quarter Earnings Announcement for January 9

Intel

Moderna

The S&P 500 has hit record levels this year and many stocks have generated fantastic returns for investors. But there's been no shortage of struggling investments, either.

Is Now the Time to Buy 3 of the S&P 500's Worst-Performing Stocks of 2024?

Celsius Holdings

Century Aluminum

Concentrix Corporation 

Corsair Gaming

Sprinklr

Flagstar Financial Inc

GEO Group

Hims & Hers Health

Jefferies Financial Group Inc

Lumen Technologies

Marathon Digital Holdings

MGP Ingredients

Pitney Bowes

EchoStar

TG Therapeutics

Texas Pacific Land Trust

Titan

ViaSat

Difficult-to-short stocks often trade at artificially inflated, unsustainable prices.

20 stocks likely to lag the S&P 500 over the next year — for this one reason

eBay

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots (NASDAQ:WBA): IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE JAMES CLEM, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,   Plaintiff, v.   JAMES A. SKINNER, STEFANO PESSINA, WILLIAM C. FOOTE, NANCY M. SCHLICHTING, GINGER L. GRAHAM, DAVID J. BRAILER, JANICE M. BABIAK, DOMINIC P. MURPHY, JOHN A. LEDERER, JOSÉ E. ALMEIDA, GEORGE R. FAIRWEATHER, and LEONARD D. SCHAEFFER,   Defendants, -and-   WALGREENS BOOTS ALLIANCE, INC.

Walgreens Boots Alliance Provides Notice of Pending and Proposed Settlement of Shareholder Derivative Action

CVS Health

As the formal review process for rescheduling cannabis unfolds, industry players are closely watching its potential to transform the sector. With the DEA hearing delayed until early 2025 and a possible Trump presidency adding uncertainty, cannabis businesses are preparing for what rescheduling to Schedule III could mean.

Pharma-Grade Cannabis Could Hit Walgreens & CVS—But Can The Industry Survive The FDA?

Tim Barry is leaving as chief executive officer of VillageMD, the clinic operator that has cost its majority owner, Walgreens Boots Alliance, billions of dollars in financial losses.

Tim Barry Is Out As CEO Of Walgreens Clinic Partner VillageMD

NVIDIA

Less than two weeks ago, Wall Street and investors were privy to one of the most important data releases of the fourth quarter -- and no, I'm not talking about the October inflation report.

Billionaire Israel Englander Sold 70% of Millennium's Stake in Nvidia and Is Piling Into a Supercharged Dividend Stock With a Nearly 12% Yield

Apollo Commercial Real Estate Finance

Cheniere Energy Partners

Kohl's

Solar Capital

Western Union

It's hard to find a hater right now. Wall Street analysts have Buy ratings on more than 75% of the S&P 500 at the moment.

Why Is The Smart Money So Down On These Monster Dividends?

Is Walgreens' High-Yielding Dividend Safe?

News for Walgreens Stock (WBA)